{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:06:30Z","timestamp":1773198390950,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The safety of ondansetron for nausea and vomiting in pregnancy (NVP) remains a subject of ongoing debate, driven by conflicting study results and a disagreement between the European Medicines Agency (EMA) and the European Network of Teratology Information Services (ENTIS) regarding its potential fetal risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the safety of using ondansetron for NVP and its possible association with major birth defects and neonatal outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective cohort study was conducted based on structured telephone follow-ups of women with NVP who contacted the NVP Helpline at a teratology information service (TIS) at the Shamir Medical Center between April 2014 and April 2018. Exposure and clinical characteristics were recorded during the initial consultation, and pregnancy and neonatal outcomes were ascertained after the estimated date of delivery using a validated questionnaire. Women treated with ondansetron formed the exposed group; controls did not receive ondansetron but could use other NVP therapies. Subgroup analyses explored the dose and frequency of use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 260 women (137 exposed; 123 controls). Baseline characteristics were broadly comparable, except for higher NVP severity in the ondansetron group, reflected by higher PUQE scores (9.86 \u00b1 2.66 vs. 8.59 \u00b1 2.49; p = 0.001) and more frequent antacid use (p = 0.001). Live birth rates (95.6% vs. 94.3%) and birth weights did not differ between groups. No differences were found in neonatal complications. Major congenital malformations were comparable between groups (5.1% vs. 4.1%; p = 0.695), with no consistent pattern identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this prospective cohort, ondansetron exposure was not associated with increased risk of adverse neonatal outcomes or major congenital malformations. The sample size limits the detection of very rare outcomes, and larger studies remain warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1783632","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:41:30Z","timestamp":1773124890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Another prospective study on the safety of ondansetron for nausea and vomiting of pregnancy: addressing ongoing concerns"],"prefix":"10.3389","volume":"17","author":[{"given":"Irina","family":"Tolchinsky","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maayan","family":"Beckinshtein","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elkana","family":"Kohn","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, Zerifin, Affiliated to the Gray Faculty of Medical & Health Sciences, Tel-Aviv University","place":["Tel Aviv, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Cohen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, Zerifin, Affiliated to the Gray Faculty of Medical & Health Sciences, Tel-Aviv University","place":["Tel Aviv, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"De-Haan","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, Zerifin, Affiliated to the Gray Faculty of Medical & Health Sciences, Tel-Aviv University","place":["Tel Aviv, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomer","family":"Ziv-Baran","sequence":"additional","affiliation":[{"name":"School of Public Health, the Gray Faculty of Medical & Health Sciences, Tel Aviv University","place":["Tel Aviv, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Stepensky","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itai","family":"Gueta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine F, The Clinical Pharmacology Unit, Tel-Aviv Medical Center, Faculty of Medicine, Tel-Aviv University","place":["Tel Aviv, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matitiahu","family":"Berkovitch","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, Zerifin, Affiliated to the Gray Faculty of Medical & Health Sciences, Tel-Aviv University","place":["Tel Aviv, Israel"]},{"name":"The Andy Lebach Chair of Clinical Pharmacology and Toxicology, The Gray Faculty of Medical & Health Sciences, Tel-Aviv University","place":["Tel Aviv, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Berlin","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, Zerifin, Affiliated to the Gray Faculty of Medical & Health Sciences, Tel-Aviv University","place":["Tel Aviv, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1097\/AOG.0000000000002456","article-title":"ACOG practice bulletin no. 189: nausea and vomiting of pregnancy","volume":"131","year":"2018","journal-title":"Obstetrics Gynecology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ajog.2013.11.035","article-title":"Hyperemesis gravidarum and long-term health of the offspring","volume":"210","author":"Ayyavoo","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.gtc.2016.02.005","article-title":"Gastrointestinal diseases in pregnancy: nausea, vomiting, hyperemesis gravidarum, gastroesophageal reflux disease, constipation, and diarrhea","volume":"45","author":"Body","year":"2016","journal-title":"Gastroenterol. Clin. North Am."},{"key":"B4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.autneu.2016.05.002","article-title":"Nausea and vomiting of pregnancy - what\u2019s new?","volume":"202","author":"Bustos","year":"2017","journal-title":"Auton. Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"951072","DOI":"10.3389\/fphar.2022.951072","article-title":"Risk of abnormal pregnancy outcomes after using ondansetron during pregnancy: a systematic review and meta-analysis","volume":"13","author":"Cao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/JCP.0000000000001630","article-title":"Reproductive safety of trazodone after maternal exposure in early pregnancy: a comparative ENTIS cohort study","volume":"43","author":"Dao","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"B7","article-title":"Ondansetron official response statement","year":"2019","journal-title":"Eur. Netw. Teratol. Inf. Serv."},{"key":"B8","unstructured":"EUROCAT guide 1.4: instruction for the registration of congenital anomalies EUROCAT guide 1.4 and reference documents (last update version 22\/11\/2021)\n          \n          \n          2013"},{"key":"B9","volume-title":"PRAC recommendations on signals","year":"2019"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/s0091-6749(99)70259-9","article-title":"Teratology: general considerations and principles","volume":"103","author":"Finnell","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ogc.2008.04.002","article-title":"Hyperemesis gravidarum","volume":"35","author":"Goodwin","year":"2008","journal-title":"Obstet. Gynecol. Clin. North Am."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1001\/jama.2018.18307","article-title":"Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring","volume":"320","author":"Huybrechts","year":"2018","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jama.2019.18587","article-title":"Intravenous ondansetron in pregnancy and risk of congenital malformations","volume":"323","author":"Huybrechts","year":"2020","journal-title":"JAMA"},{"key":"B14","unstructured":"IBM SPSS software for windows\n          \n          \n          2020"},{"key":"B15","doi-asserted-by":"publisher","first-page":"075","DOI":"10.1055\/s-0040-1722097","article-title":"Case-parent trio studies in cleft lip and palate","volume":"7","author":"Khan","year":"2020","journal-title":"Glob. Med. Genet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/14740338.2017.1361403","article-title":"Safety considerations surrounding use of treatment options for nausea and vomiting in pregnancy","volume":"16","author":"Koren","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/10547738231159062","article-title":"Ondansetron use during pregnancy: Birth defects and obstetric outcomes","volume":"32","author":"Masarwe","year":"2023","journal-title":"Clin. Nurs. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/796590","article-title":"Adherence with drug therapy in pregnancy","volume":"2012","author":"Matsui","year":"2012","journal-title":"Obstet. Gynecol. Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1056\/nejmoa1211035","article-title":"Ondansetron in pregnancy and risk of adverse fetal outcomes","volume":"368","author":"Pasternak","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/bdr2.1705","article-title":"Risk of malformation after ondansetron in pregnancy: an updated systematic review and meta-analysis","volume":"112","author":"Picot","year":"2020","journal-title":"Birth Defects Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.reprotox.2020.11.005","article-title":"Pregnancy outcome following in-utero exposure to ondansetron: a prospective comparative observational study","volume":"99","author":"Sakran","year":"2021","journal-title":"Reprod. Toxicol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.reprotox.2008.05.064","article-title":"Using observational cohort data for studying drug effects on pregnancy outcome-methodological considerations","volume":"26","author":"Schaefer","year":"2008","journal-title":"Reprod. Toxicol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200645040-00006","article-title":"Placental transfer of ondansetron during early human pregnancy","volume":"45","author":"Siu","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/1471-0528.12066","article-title":"Pregnancy outcome following maternal exposure to statins: a multicentre prospective study","volume":"120","author":"Winterfeld","year":"2013","journal-title":"BJOG"},{"key":"B25","unstructured":"Anatomical therapeutic chemical (ATC) classification\n          \n          \n          2024"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1783632\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:41:33Z","timestamp":1773124893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1783632\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":25,"alternative-id":["10.3389\/fphar.2026.1783632"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1783632","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1783632"}}